Kairos Pharma Ltd KAPA

Morningstar Rating
$0.44 −0.02 (4.62%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

KAPA is trading within a range we consider fairly valued.
Price
$0.46
Fair Value
LOCK|qN@RZkh
Uncertainty
LOCK|@T tfcl
1-Star Price
LOCK|$<pN$Qy
5-Star Price
LOCK|?@%YwRP
Economic Moat
LOCK|V><k
Capital Allocation
—

News

Trading Information

Previous Close Price
$0.46
Day Range
$0.41–0.47
52-Week Range
$0.38–7.28
Bid/Ask
$0.37 / $0.47
Shares Outstanding
4.69M
Market Cap
$2.04M
Volume/Avg
33,757 / 355,043

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
1

Valuation

Metric
KAPA
Price/Earnings (Normalized)
—
Price/Book Value
0.42
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
KAPA
Quick Ratio
6.31
Current Ratio
6.77
Interest Coverage
—
Quick Ratio
KAPA

Profitability

Metric
KAPA
Return on Assets (Normalized)
−99.65%
Return on Equity (Normalized)
−106.18%
Return on Invested Capital (Normalized)
−108.73%
Return on Assets
KAPA

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|^&VVPHLOCK|D@@#$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|@Qm@Y$@LOCK|&Gxt&$95B
Moderna Inc
MRNA
LOCK|knDd!y&LOCK|@^$79B
argenx SE ADR
ARGX
LOCK|Kb>r$sLOCK|W%Z$59B
BeOne Medicines Ltd ADR
ONC
LOCK|&!h^!#LOCK|%<$45B
Royalty Pharma PLC Class A
RPRX
LOCK|&Hq<$^cLOCK|^R>$$30B
Incyte Corp
INCY
LOCK|bsnz>d%LOCK|?N?$23B
BioNTech SE ADR
BNTX
LOCK|m>S^&%LOCK|h@%$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|>nkfpWLOCK|<Rvf%$19B
BridgeBio Pharma Inc
BBIO
LOCK|T@Jx>!dLOCK|$KQ$15B

Sponsor Center